<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>225-FENOFIBRATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENOFIBRATE" rxcui="8703">
<ATC code="C10AB05" />
<ATC code="C10BA03" />
<ATC code="C10BA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the nephrotoxicity of the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring of the renal function, during and after the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>225-FENOFIBRATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENOFIBRATE" rxcui="8703">
<ATC code="C10AB05" />
<ATC code="C10BA03" />
<ATC code="C10BA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EZETIMIBE" rxcui="341248">
<ATC code="C10BA05" />
<ATC code="C10AX09" />
<ATC code="C10BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of gallstones due to increase of the biliary excretion of cholesterol</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
